

## TABLE OF CONTENTS

<b>ABSTRACT</b>	<b>i</b>
<b>ABSTRAK</b>	<b>iv</b>
<b>ACKNOWLEDGEMENTS</b>	<b>vii</b>
<b>TABLE OF CONTENTS</b>	<b>viii</b>
<b>LIST OF ABBREVIATIONS</b>	<b>xii</b>
<b>LIST OF TABLES</b>	<b>xv</b>
<b>LIST OF FIGURES</b>	<b>xvii</b>
<b>CHAPTER 1 INTRODUCTION</b>	<b>1</b>
<b>CHAPTER 2 LITERATURE REVIEW</b>	<b>7</b>
<b>2.1 Cervical Neoplasms</b>	<b>7</b>
2.1.1 Epidemiology	8
2.1.2 Aetiology	11
2.1.2.i Virus	11
2.1.2.i.a Human Papillomavirus	11
2.1.2.i.b Human Herpes Simplex Virus	15
2.1.2.i.c Epstein-Barr Virus	16
2.1.2.i.d Human Cytomegalovirus	18
2.1.2.ii Oncogenes	18
2.1.2.iii Marital and Sexual Factors	19
2.1.2.iv Menstrual or Reproductive Factors	20
2.1.2.v Male Sex Behaviour	20
2.1.2.vi Cigarette Smoking	21
2.1.2.vii Oral Contraceptives	21
2.1.2.viii Dietary Factors	22
2.1.3 Classification and Staging	22
2.1.4 Diagnosis	22
2.1.5 Clinical Symptoms	24
2.1.6 Treatment and Management	24
2.1.6.i Microinvasive Carcinoma/Carcinoma <i>in situ</i>	24
2.1.6.ii Invasive Carcinoma	24
2.1.6.iii Special Circumstances	25
<b>2.2 Ovarian Cancer</b>	<b>26</b>
2.2.1 Epidemiology	26
2.2.2 Aetiology	27
2.2.2.i Virus	27
2.2.2.ii Oncogenes	27
2.2.2.iii Reproductive and Hormonal Effect	29
2.2.2.iv Oral Contraceptives	29
2.2.2.v Family History	30

2.2.2.vi	Molecular Genetic Changes	31
2.2.2.vii	Blood Groups	32
2.2.2.viii	Environmental Factors	32
2.2.3	Classification and Staging	33
2.2.4	Clinical Symptoms	33
2.2.5	Diagnosis	34
2.2.6	Treatment and Management	35
2.2.6.i	Surgery	35
2.2.6.ii	Adjuvant Therapy	35
2.2.6.iii	Hormonal Therapy	36
<b>2.3</b>	<b>Endometrial Cancer</b>	<b>37</b>
2.3.1	Epidemiology	37
2.3.2	Aetiology	38
2.3.2.i	Socioeconomic Factors	38
2.3.2.ii	Anthropometric Variables	38
2.3.2.iii	Reproductive and Hormonal Factors	39
2.3.2.iv	Medical History	40
2.3.2.v	Dietary Factors	40
2.3.2.vi	Estrogen Replacement Therapy	40
2.3.2.vii	Oral Contraceptives	41
2.3.2.viii	Cigarette Smoking	41
2.3.3	Classification and Staging	41
2.3.4	Clinical Symptoms	43
2.3.5	Diagnosis	43
2.3.6	Treatment and Management	44
<b>2.4</b>	<b>Cancer of the Vulva and Vagina</b>	<b>46</b>
2.4.1	Cancer of the Vulva	46
2.4.2	Cancer of the Vagina	46
2.4.3	Epidemiology	47
2.4.4	Aetiology	47
2.4.4.i	Social Factors	47
2.4.4.ii	Obesity and Reproductive Factors	48
2.4.4.iii	Viral Factor	48
2.4.5	Classification and Staging	48
2.4.6	Clinical Symptoms	50
2.4.7	Diagnosis	50
2.4.8	Treatment	50
<b>CHAPTER 3</b>	<b>MATERIALS AND METHODS</b>	<b>51</b>
<b>3.1</b>	<b>EPIDEMIOLOGY OF GYNAECOLOGICAL NEOPLASMS</b>	<b>51</b>
3.1.1	Collection of Epidemiological Data	51
3.1.2	Analysis of Data	51

<b>3.2</b>	<b>SEROLOGY OF CERVICAL CARCINOMA</b>	<b>52</b>
3.2.1	Collection of sera samples	52
3.2.2	Detection of IgA, IgG and IgM Antibodies Against HPV Type 16	52
3.2.2.i	Antigen Coating	53
3.2.2.ii	Blocking of Plates	53
3.2.2.iii	Detection of Antibodies	53
3.2.3	Detection of IgG Antibody to CMV and HSV-II	55
3.2.4	Cell Cultures and Maintenance	58
3.2.4.i	Cell Lines	58
3.2.4.ii	Revival of Cells	58
3.2.4.iii	Maintenance of Cells	59
3.2.4.iv	Cryopreservation of Cells	59
3.2.5	Detection of IgA and IgG Antibodies to EBV-VCA and IgG Antibody to EBV-EA	60
3.2.5.i	Enhancement of EBV Antigen Expression	60
3.2.5.i.a	VCA Expression in P3HR-1	60
3.2.5.i.b	EA Expression in Raji	60
3.2.5.ii	Harvesting of Cells	61
3.2.5.iii	Indirect Immunofluorescence Assay	62
<b>CHAPTER 4</b>	<b>RESULTS</b>	<b>64</b>
<b>4.1</b>	<b>EPIDEMIOLOGY OF GYNAECOLOGICAL NEOPLASMS</b>	<b>64</b>
4.1.1	Incidence of gynaecological neoplasms in Sarawak	64
4.1.2	Most frequent gynaecological neoplasms in Sarawak	64
4.1.3	Incidence of gynaecological neoplasms in Sarawak with respect to age	68
4.1.4	Incidence of gynaecological neoplasms in Sarawak with respect to ethnic group	71
4.1.5	Incidence of gynaecological neoplasms in Sarawak with respect to ethnic group and cancer sites	74
4.1.6	Ethnic composition with respect to cancer sites	77
4.1.7	Incidence of cervical neoplasm in Sarawak	80
4.1.8	Incidence of cervical neoplasm in Sarawak with respect to age	80
<b>4.2</b>	<b>SEROLOGY OF CERVICAL CARCINOMA</b>	<b>84</b>
4.2.1	Seroprevalence of HPV 16 E7 in cervical carcinoma patients and normal pregnant women	84
4.2.2	Seroprevalence of HSV-II and CMV in cervical carcinoma patients and normal pregnant women	85
4.2.3	Seroprevalence of EBV-associated antibody titres in cervical carcinoma patients and normal pregnant women	86
4.2.4	Seroprevalence of HSV-II, CMV and EBV in HPV-seropositive and HPV-seronegative cervical carcinoma patients	87

4.2.5	Seroprevalence of HSV-II, CMV and EBV in HPV-seropositive and HPV-seronegative normal pregnant women	88
<b>CHAPTER 5 DISCUSSION</b>		90
5.1	<b>EPIDEMIOLOGY OF GYNAECOLOGICAL NEOPLASMS IN SARAWAK</b>	90
5.2	<b>SEROEPIDEMIOLOGY OF HPV 16, HSV-II, CMV AND EBV ANTIGEN IN CERVICAL CARCINOMA</b>	100
5.2.1	Seroprevalence of HPV 16 E7	100
5.2.2	Seroprevalence of HSV-II	103
5.2.3	Seroprevalence of EBV	106
5.2.4	Seroprevalence of CMV	107
5.2.5	Seroprevalence of HSV-II, CMV and EBV in cervical carcinoma cases according to HPV seropositivity status	108
<b>CONCLUSION</b>		110
<b>REFERENCES</b>		112
<b>APPENDIX</b>		141